106 related articles for article (PubMed ID: 30836254)
1. Accuracy of [
Fassbender TF; Schiller F; Mix M; Maecke HR; Kiefer S; Drendel V; Meyer PT; Jilg CA
Nucl Med Biol; 2019 Mar; 70():32-38. PubMed ID: 30836254
[TBL] [Abstract][Full Text] [Related]
2. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
6. Correlation of
Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
[No Abstract] [Full Text] [Related]
7. Voxel-based comparison of [
Fassbender TF; Schiller F; Zamboglou C; Drendel V; Kiefer S; Jilg CA; Grosu AL; Mix M
EJNMMI Res; 2020 Jun; 10(1):62. PubMed ID: 32533273
[TBL] [Abstract][Full Text] [Related]
8. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
10.
Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
[TBL] [Abstract][Full Text] [Related]
11. Association between gastrin-releasing peptide receptor expression as assessed with [
Michalski K; Stoykow C; Bronsert P; Juhasz-Böss I; Meyer PT; Ruf J; Erbes T; Asberger J
Nucl Med Biol; 2020; 86-87():37-43. PubMed ID: 32473549
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Study of
Duan H; Ghanouni P; Daniel B; Rosenberg J; Davidzon GA; Aparici CM; Kunder C; Sonn GA; Iagaru A
J Nucl Med; 2023 Apr; 64(4):592-597. PubMed ID: 36328488
[TBL] [Abstract][Full Text] [Related]
13. PET Using a GRPR Antagonist
Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X
J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014
[TBL] [Abstract][Full Text] [Related]
14. Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonist
Vats K; Sharma R; Kameswaran M; Satpati D; Dash A
J Pharm Biomed Anal; 2019 Jan; 163():39-44. PubMed ID: 30278325
[No Abstract] [Full Text] [Related]
15. (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison.
Zamboglou C; Schiller F; Fechter T; Wieser G; Jilg CA; Chirindel A; Salman N; Drendel V; Werner M; Mix M; Meyer PT; Grosu AL
Theranostics; 2016; 6(10):1619-28. PubMed ID: 27446496
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
Schollhammer R; de Clermont Gallerande H; Robert G; Yacoub M; Vimont D; Hindié E; Fernandez P; Morgat C
Clin Nucl Med; 2019 Sep; 44(9):e535-e536. PubMed ID: 31246685
[TBL] [Abstract][Full Text] [Related]
17. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
18. Intraindividual Comparison of
Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
[No Abstract] [Full Text] [Related]
19. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]